Study Showed Epratuzumab In Combination With Rituximab And Chemotherapy Is Safe, Tolerable, And Active In Aggressive Lymphoma

... Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company focused on developing monoclonal antibodies, today reported that adding epratuzumab to rituximab and combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) to treat patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) produced promising results. [click link for full article] ...